Frontlight ResearchEarly access
Acute myeloid leukaemia trials in United States
334 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peoplePharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
- Where
- Atlanta, New York
- Age
- 12 years and over
- People
- 50
- Run by
- Meryx, Inc.
See details and how to joinNCT04872478 - Phase 1Taking peopleVenetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
- Where
- The Bronx
- Age
- 18 years to 75 years
- People
- 99
- Run by
- Montefiore Medical Center
See details and how to joinNCT05342584 - Phase 1Taking peopleVenetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Where
- Miami
- Age
- 18 years and over
- People
- 18
- Run by
- Terrence J Bradley, MD
See details and how to joinNCT05597306 - Phase 2Taking peopleMetabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- Where
- Sacramento, The Bronx, White Plains
- Age
- 18 years and over
- People
- 91
- Run by
- Montefiore Medical Center
See details and how to joinNCT05184842 - Phase 1Taking peopleDose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia
- Where
- Atlanta, Chapel Hill, Chicago, Cincinnati, College Park, Columbus, Dallas, Lawrence, Los Angeles, New York, Portland, San Francisco
- Age
- 18 years and over
- People
- 150 worldwide
- Run by
- Lomond Therapeutics Holdings, Inc.
See details and how to joinNCT06366789 - Phase 1Taking peoplePLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
- Where
- Seattle
- Age
- Up to 30 years
- People
- 18
- Run by
- Seattle Children's Hospital
See details and how to joinNCT05105152 - No phaseTaking peopleHome Blood Transfusions
- Where
- Philadelphia
- Age
- 18 years and over
- People
- 30
- Run by
- Thomas Jefferson University
See details and how to joinNCT07121140 - Phase 1/2Taking peopleClinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
- Where
- Charlotte, Houston, Winston-Salem
- Age
- 18 years and over
- People
- 49
- Run by
- ARCE Therapeutics, Inc.
See details and how to joinNCT06680752 - Phase 1Taking peopleVyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
- Where
- Tampa
- Age
- 18 years and over
- People
- 22
- Run by
- H. Lee Moffitt Cancer Center and Research Institute
See details and how to joinNCT05024552 - Phase 2Taking peopleHSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- Where
- Cincinnati, New York, Seattle
- Age
- 3 months and over
- People
- 70
- Run by
- Children's Hospital Medical Center, Cincinnati
See details and how to joinNCT02143830 - Phase 1/2Not yet taking people in United StatesPhase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML
- Where
- Columbus
- Age
- 1 year to 39 years
- People
- 42
- Run by
- Nationwide Children's Hospital
See details and how to joinNCT07026942 - No phaseTaking peopleNovel Digital Application for Patients With Acute Leukemia
- Where
- Boston, Durham, Seattle
- Age
- 18 years to 120 years
- People
- 200
- Run by
- Massachusetts General Hospital
See details and how to joinNCT06472128 - Phase 1Taking peopleStudy of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Where
- Atlanta, Augusta, Baltimore, Birmingham, Cleveland, Duarte, Houston, Seattle
- Age
- 18 years and over
- People
- 242 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT04260022 - Phase 1Taking peopleABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- Where
- Boston, Buffalo, Chicago
- Age
- 18 years and over
- People
- 40
- Run by
- Marlise Luskin, MD
See details and how to joinNCT03595917 - Phase 1Taking peopleStudy of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Where
- Atlanta, Aurora, Canton, Duarte, Houston, Newark, Rochester
- Age
- 18 years and over
- People
- 124
- Run by
- Nerviano Medical Sciences
See details and how to joinNCT06549790 - Phase 2Taking peopleTwo Step Haplo With Radiation Conditioning
- Where
- Philadephia
- Age
- 18 years and over
- People
- 63
- Run by
- Thomas Jefferson University
See details and how to joinNCT05031897 - Phase 1Taking peopleIS-free Treg HaploHCT
- Where
- Boston
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Dana-Farber Cancer Institute
See details and how to joinNCT04678401 - Phase 1Enrolling by invitationA Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML
- Where
- Burlington
- Age
- 18 years and over
- People
- 20
- Run by
- University of Vermont
See details and how to joinNCT07014462 - Phase 1/2Not yet taking people in United StatesAB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Where
- Houston
- Age
- 18 years and over
- People
- 78 worldwide
- Run by
- AB Science
See details and how to joinNCT05211570 · EU 2024-516641-39-00 - Phase 1Taking peopleA Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- Where
- Buffalo, Chicago, Columbus, Duarte, Houston, Los Angeles, Madison, Miami, Nashville, New York, Palo Alto, Seattle, Tampa
- Age
- 18 years and over
- People
- 170
- Run by
- BlossomHill Therapeutics
See details and how to joinNCT06501196 - Phase 1/2Taking peopleClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Where
- Atlanta, Birmingham, Boston, Cleveland, Columbus, Duarte, Durham, Huston, Irvine, La Jolla, Los Angeles, Miami, New Haven, Palo Alto, Sacramento
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Aptose Biosciences Inc.
See details and how to joinNCT03850574 · EU 2023-503244-14-00 - No phaseTaking peopleSpecialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Where
- Atlanta, Baltimore, Birmingham, Bloomington, Boston, Chapel Hill, Columbus, Denver, Durham, Evanston, Madison, Miami, Philadelphia, Portland, Rochester, Seattle, Stanford, Tampa
- Age
- 18 years to 120 years
- People
- 2,300
- Run by
- Massachusetts General Hospital
See details and how to joinNCT05237258 - Phase 1Taking peopleAPVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
- Where
- Canton, Cincinnati, Dallas, Denver, Fairway, Houston, Miami
- Age
- 18 years and over
- People
- 39
- Run by
- Aptevo Therapeutics
See details and how to joinNCT06634394 - Phase 2Enrolling by invitationKIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children
- Where
- Chicago, Los Angeles, Milwaukee, Nashville, Oakland, Palo Alto, Philadelphia, Salt Lake City, San Diego, San Francisco, Valhalla
- Age
- Up to 21 years
- People
- 50
- Run by
- Michael Pulsipher
See details and how to joinNCT02646839 - Phase 2Enrolling by invitationDonor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant
- Where
- Aurora, Chicago, Cleveland, Columbus, Los Angeles, Milwaukee, Orlando, Phoenix, Salt Lake City, Seattle, St Louis, St. Petersburg, Valhalla
- Age
- 0 years to 25 years
- People
- 30
- Run by
- Michael Pulsipher
See details and how to joinNCT04836390